SCHEMBL6790256

SCHEMBL6790256

O=C1OC(c2ccccc2)=N/C1=C\c1cccc([N+](=O)[O-])c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAPK3 O43293 7/20 0.61
ALDH1A1 P00352 3/20 0.53
MAPT P10636 3/20 0.53
PLCG2 P16885 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
NOTUM Q6P988 1/20 0.52
CSNK2A2 P19784 1/20 0.51
CSNK2B P67870 1/20 0.51
CSNK2A1 P68400 1/20 0.51
NFE2L2 Q16236 1/20 0.50
F2 P00734 1/20 0.50
F10 P00742 1/20 0.50
PLG P00747 1/20 0.50
PLAU P00749 1/20 0.50
PLAT P00750 1/20 0.50
KLKB1 P03952 1/20 0.50
KDM4E B2RXH2 2/20 0.49
NR1H4 Q96RI1 1/20 0.49
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6790260 1.00 DAPK3 (0.61) DAPK3ALDH1A1MAPTPLCG2MEN1
SCHEMBL6793839 0.86 DAPK3 (0.68) DAPK3ALDH1A1MAPTPLCG2MEN1
SCHEMBL6794629 0.86 DAPK3 (0.76) DAPK3ALDH1A1MAPTPLCG2MEN1
SCHEMBL6793830 0.86 DAPK3 (0.68) DAPK3ALDH1A1MAPTPLCG2MEN1
SCHEMBL6794631 0.86 DAPK3 (0.76) DAPK3ALDH1A1MAPTPLCG2MEN1
SCHEMBL31537079 0.85 DAPK3 (0.51) DAPK3ALDH1A1MAPTPLCG2MEN1
SCHEMBL31537076 0.85 DAPK3 (0.51) DAPK3ALDH1A1MAPTPLCG2MEN1
SCHEMBL6796902 0.83 DAPK3 (0.58) DAPK3ALDH1A1MAPTPLCG2MEN1
SCHEMBL6796899 0.83 DAPK3 (0.58) DAPK3ALDH1A1MAPTPLCG2MEN1
SCHEMBL6794799 0.82 ALDH1A1 (0.59) DAPK3ALDH1A1MAPTPLCG2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 DAPK3 1049/4885ALDH1A1 905/4885MAPT 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.